Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evoke Pharma (EVOK) Consolidated Net Income (2020 - 2025)

Historic Consolidated Net Income for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to -$1.2 million.

  • Evoke Pharma's Consolidated Net Income rose 1190.06% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.2 million, marking a year-over-year increase of 1497.85%. This contributed to the annual value of -$5.4 million for FY2024, which is 3131.43% up from last year.
  • According to the latest figures from Q3 2025, Evoke Pharma's Consolidated Net Income is -$1.2 million, which was up 1190.06% from -$1.6 million recorded in Q2 2025.
  • Evoke Pharma's Consolidated Net Income's 5-year high stood at -$1.2 million during Q3 2025, with a 5-year trough of -$2.7 million in Q1 2021.
  • For the 5-year period, Evoke Pharma's Consolidated Net Income averaged around -$1.8 million, with its median value being -$1.8 million (2022).
  • As far as peak fluctuations go, Evoke Pharma's Consolidated Net Income skyrocketed by 6712.34% in 2021, and later tumbled by 2397.05% in 2025.
  • Evoke Pharma's Consolidated Net Income (Quarter) stood at -$1.7 million in 2021, then fell by 7.82% to -$1.8 million in 2022, then dropped by 10.21% to -$2.0 million in 2023, then skyrocketed by 39.98% to -$1.2 million in 2024, then increased by 3.06% to -$1.2 million in 2025.
  • Its last three reported values are -$1.2 million in Q3 2025, -$1.6 million for Q2 2025, and -$1.3 million during Q1 2025.